Skip to main content
. 2021 Jan 22;11:2121. doi: 10.1038/s41598-021-81486-z

Figure 3.

Figure 3

Antiplasmodial activity, toxicity and stability profiles of the prioritized hits NCGC00374598 and NCGC00473217. Compound activity profiles for NCGC00374598 (compound 1) and NCGC00473217 (compound 2) against P. falciparum asexual blood stage parasites (black line, circle), as well as P. berghei liver stages in either laboratory A (blue line, squares) or laboratory B (purple line, triangles). Percent inhibition is shown on the Y-axis and compound concentration (Log [M]) is shown on the X-axis. Also shown are activities against P. falciparum Dd2 ABS parasites, in vitro inhibition activity in the P. berghei liver stage development assay (ILSDA), toxicity against mammalian HepG2 cells, and half-life rat liver microsome stability (RLM) values. Mean ± SD values were derived from of at least three independent replicates.